Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7220-7228

  Fracasso, Paula M ^a,e   Goldstein, Lori J ^b   De Alwis, Dinesh P ^c   Rader, Janet S ^a   Arquette, Matthew A ^a   Goodner, Sherry A ^a   Wright, Lisa P ^a   Fears, Carole L ^a   Gazak, Robert J ^c   Andre, Valerie A M ^c   Burgess, Michael F ^c   Slapak, Christopher A ^c   Schellens, Jan H M ^d  

^a USA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DEXAMETHASONE; DOCETAXEL; GLYCOPROTEIN P INHIBITOR; HEMOGLOBIN; ZOSUQUIDAR;

ADRENAL CANCER; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HALLUCINATION; HEAD AND NECK CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY CANCER; LIVER TOXICITY; LUNG CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MOTOR NEUROPATHY; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SENSORY NEUROPATHY; SKIN DISEASE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DIBENZOCYCLOHEPTENES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; P-GLYCOPROTEIN; QUINOLINES; TAXOIDS; TIME FACTORS;

EID: 8444251671     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0452     Document Type: Article

References (20)

1. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 1997;40(Suppl):S3-8.
2. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
3. Ford J, Yang JM, Hait W. P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. In: Hait W, editor. Norwell, MA: Kluwer Academic Publishers; 1996. p. 3-38.
4. Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-8.
5. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993;53:4837-42.
6. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-42.
7. Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-15.
8. Fracasso PM, Westerveldt P, Fears CA, et al. Phase I study of paclitaxel in combination with multidrug resistance modulator, PSC 833 (valspodar), in refractory malignancies. J Clin Oncol 2000;18:1124-34.
9. Chico I, Kang MH, Bergan R, et al. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 2001;19:832-42.
10. Dantzig AH, Shepard RL, Cao J, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-9.
11. Rubin EH, de Alwis DP, Pouliquen I, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar. 3HCI trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies. Clin Cancer Res 2002;8:3710-7.
12. Sandler A, Gordon M, de Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 2004;10:3265-3272.
13. Vergniol JC, Bruno R, Montay G, Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 1992;582:273-8.
14. Nallani SC, Genter MB, Desai PB. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 2001;48:115-22.
15. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin N Am 1995;9:363-82.
16. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90.
17. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
18. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-96.
19. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997;48:353-74.
20. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (Bethesda) 1997;89:917-31.